Projects per year
Personal profile
Personal profile
Dr. Ganguly is a board-certified hematologist specializing in the clinical care and research of hematological malignancies, cellular therapeutics, and bone marrow transplantation. Dr. Ganguly was a A. Drue Jennings endowed professor of medical oncology at the University of Kansas Cancer Center in Westwood, Kansas where he was also the Deputy Director of the Division of Hematological Malignancies and Cellular Therapeutics, the Associate Director of Blood and Marrow Transplantation Program, and the Director of Lymphoma and Myeloma Program.
Dr. Ganguly received his undergraduate degree from Calcutta Medical College and his medical degree from the Department of Internal Medicine, Post Graduate, Institute of Medical Education and Research in India. Additionally, he completed his residency in internal medicine and fellowship in hematology at Baylor College of Medicine and concluded another fellowship in bone marrow transplantation at Baylor College of Medicine, Center for Cell and Gene Therapy.
Research Area Keywords
- Cancer
Fingerprint
Dive into the research topics where Siddhartha Ganguly is active. These topic labels come from the works of this person. Together they form a unique fingerprint.
- 1 Similar Profiles
Network
Recent external collaboration on country/territory level. Dive into details by clicking on the dots or
Projects
- 5 Active
-
Phase III_Parsaclisib and Ruxolitinib_Myelofibrosis_INCB 50465-313 A Phase 3, Randomized, Double-Blind, Placebo-Controlled Study of the Combination of PI3K Inhibitor Parsaclisib and Ruxolitinib in Participants With Myelofibrosis
Shah, S., Darcourt, J., Ganguly, S., Petkova, J., Pingali, S. R. & Rice, L.
8/27/21 → …
Project: Clinical Trial
-
Phase 3_NavitoclaxRuxolitinib_Myelofibrosis_Abbvie M20-178 Transform-2
Shah, S., Darcourt, J., Ganguly, S., Pingali, S. R. & Rice, L.
6/7/21 → …
Project: Clinical Trial
-
Phase II_PevonedistatVenetoclaxAzacitidine_AML_Pevonedistat-2002Takeda A Randomized, Open-label, Controlled, Phase 2 Study of Pevonedistat, Venetoclax, and Azacitidine Versus Venetoclax Plus Azacitidine in Adults With Newly Diagnosed Acute Myeloid Leukemia Who Are Unfit for Intensive Chemotherapy
Shah, S., Darcourt, J., Ganguly, S., Petkova, J., Pingali, S. R. & Rice, L.
4/30/21 → …
Project: Clinical Trial
-
A Phase 2 Open-label Study of Brentuximab Vedotin in Front-line Therapy of Hodgkin Lymphoma (HL) an dCD30-expressing Peripheral T-cell Lymphoma (PTCL) in Older Patients or Patients With Significant Comorbidities Ineligible for Standard Chemotherapy
Pingali, S. R., Darcourt, J., Ganguly, S., Petkova, J., Rice, L. & Shah, S.
7/8/20 → …
Project: Clinical Trial
-
A Phase 2, Multicenter, Single-arm Study of Retreatment With Brentuximab Vedotin in Subjects With Relapsed or Refractory Classic Hodgkin Lymphoma (cHL) or CD30-expressing Peripheral T Cell Lymphoma (PTCL)
Pingali, S. R., Abdelrahim, M., Bernicker, E. H., Chang, J. C., Darcourt, J., Ganguly, S., Heyne, K., Niravath, P. A., Petkova, J., Rice, L., Shah, S. & Singh, M.
7/8/20 → …
Project: Clinical Trial
-
Community health status and outcomes after allogeneic hematopoietic cell transplantation in the United States
Hong, S., Brazauskas, R., Hebert, K. M., Ganguly, S., Abdel-Azim, H., Diaz, M. A., Beattie, S., Ciurea, S. O., Szwajcer, D., Badawy, S. M., Gratwohl, A. A., LeMaistre, C., Aljurf, M. D. S. M., Olsson, R. F., Bhatt, N. S., Farhadfar, N., Yared, J. A., Yoshimi, A., Seo, S., Gergis, U. & 20 others, , Feb 15 2021, In: Cancer. 127, 4, p. 609-618 10 p.Research output: Contribution to journal › Article › peer-review
1 Scopus citations -
Concentration–QTc analysis of quizartinib in patients with relapsed/refractory acute myeloid leukemia
Kang, D., Ludwig, E., Jaworowicz, D., Huang, H., Fiedler-Kelly, J., Cortes, J., Ganguly, S., Khaled, S., Krämer, A., Levis, M., Martinelli, G., Perl, A., Russell, N., Abutarif, M., Choi, Y. & Yin, O., Apr 2021, In: Cancer Chemotherapy and Pharmacology. 87, 4, p. 513-523 11 p.Research output: Contribution to journal › Article › peer-review
Open Access -
Correction: Allogeneic transplantation in elderly patients ≥65 years with non-Hodgkin lymphoma: a time-trend analysis (Blood Cancer Journal, (2019), 9, 12, (97), 10.1038/s41408-019-0261-1)
Shah, N. N., Ahn, K. W., Litovich, C., Sureda, A., Kharfan-Dabaja, M. A., Awan, F. T., Ganguly, S., Gergis, U., Inwards, D., Karmali, R., Lazaryan, A., Lekakis, L., Munshi, P., Nathan, S., Saad, A. A., Solh, M., Steinberg, A., Vij, R., Wood, W. A., Fenske, T. S. & 2 others, , Apr 2021, In: Blood Cancer Journal. 11, 4, 82.Research output: Contribution to journal › Comment/debate › peer-review
Open Access -
Correction: Impact of autologous blood transfusion after bone marrow harvest on unrelated donor’s health and outcome: a CIBMTR analysis (Bone Marrow Transplantation, (2020), 55, 11, (2121-2131), 10.1038/s41409-020-0911-8)
Farhadfar, N., Murthy, H. S., Logan, B. R., Sees, J. A., Ayas, M., Battiwalla, M., Beitinjaneh, A. M., Chhabra, S., Diaz, M. A., Engles, K., Frangoul, H., Ganguly, S., Gergis, U., Kamani, N. R., Kamble, R. T., Kasow, K. A., Lazarus, H. M., Liesveld, J. L., Norkin, M., O’ Donnell, P. V. & 17 others, , Feb 2021, In: Bone Marrow Transplantation. 56, 2, p. 522 1 p.Research output: Contribution to journal › Comment/debate › peer-review
Open Access -
Correction to: Impact of depth of clinical response on outcomes of acute myeloid leukemia patients in first complete remission who undergo allogeneic hematopoietic cell transplantation (Bone Marrow Transplantation, (2021), 10.1038/s41409-021-01261-6)
Percival, M. E., Wang, H. L., Zhang, M. J., Saber, W., de Lima, M., Litzow, M., Kebriaei, P., Abdel-Azim, H., Adekola, K., Aljurf, M., Bacher, U., Badawy, S. M., Beitinjaneh, A., Bejanyan, N., Bhatt, V., Byrne, M., Cahn, J. Y., Castillo, P., Chao, N., Chhabra, S. & 47 others, , 2021, (Accepted/In press) In: Bone Marrow Transplantation.Research output: Contribution to journal › Comment/debate › peer-review
Open Access